Zhou Xinghong, Liu Ya, Xie Jiahui, Wen Ziqi, Yang Jiaqi, Zhang Hanyue, Zhou Zijing, Zhang Jinyu, Cui Huixian, Ma Jun
Stem Cell Research Center, Hebei Medical University, Hebei Province, 050017, China.
Hebei Research Center for Stem Cell Medical Translational Engineering, Hebei Province, 050017, China.
Curr Stem Cell Res Ther. 2025;20(1):72-82. doi: 10.2174/1574888X18666230817111559.
Pulmonary fibrosis (PF) is a fatal disease distinguished by structural destruction and dysfunction, accompanied by continuous accumulation of fibroblasts, which eventually leads to lung failure. Preclinical studies have shown that the administration of mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) may be a safe and effective treatment for PF. The purpose of our meta-analysis is to evaluate the efficacy of MSC-EVs therapy and identify therapeutic aspects related to PF.
Our study (up to April 6, 2022) identified English and Chinese, preclinical, controlled, and in vivo studies to examine the application of MSC-EVs in the treatment of PF. The risk of bias (ROB) is assessed using the SYRCLE bias risk tool. The primary outcomes include collagen content, α-smooth muscle actin (α-SMA), hydroxyproline (HYP) content, and transforming growth factor-β1 (TGF-β1).
Thirteen studies were included in this meta-analysis. Ten studies evaluated the collagen content, five studies evaluated the α-SMA, five studies evaluated the HYP content, and six studies evaluated the TGF-β1. Compared to the control group, MSC-EVs therapy was associated with a significant reduction of collagen accumulation, α-SMA, HYP content, and TGF-β1.
The administration of MSC-EVs is beneficial for the treatment of rodent PF models. However, the safety and effectiveness of the application in human PF diseases have yet to be confirmed. The application of MSC-EVs in the treatment of PF needs to be further standardized in terms of source, route of administration, and culture method.
肺纤维化（PF）是一种致命疾病，其特征为结构破坏和功能障碍，伴有成纤维细胞持续积聚，最终导致肺衰竭。临床前研究表明，给予间充质干细胞衍生的细胞外囊泡（MSC-EVs）可能是治疗PF的一种安全有效的方法。我们的荟萃分析旨在评估MSC-EVs治疗的疗效，并确定与PF相关的治疗方面。
我们的研究（截至2022年4月6日）检索了英文和中文的临床前、对照和体内研究，以考察MSC-EVs在PF治疗中的应用。使用SYRCLE偏倚风险工具评估偏倚风险（ROB）。主要结局包括胶原蛋白含量、α平滑肌肌动蛋白（α-SMA）、羟脯氨酸（HYP）含量和转化生长因子-β1（TGF-β1）。
本荟萃分析纳入了13项研究。10项研究评估了胶原蛋白含量，5项研究评估了α-SMA，5项研究评估了HYP含量，6项研究评估了TGF-β1。与对照组相比，MSC-EVs治疗与胶原蛋白积聚、α-SMA、HYP含量和TGF-β1的显著降低相关。
给予MSC-EVs对啮齿动物PF模型的治疗有益。然而，其在人类PF疾病中的应用安全性和有效性尚未得到证实。MSC-EVs在PF治疗中的应用在来源、给药途径和培养方法方面需要进一步规范。
